Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Clinical trial NCT02268253 · COMPLETED
Trial details
- NCT number
- NCT02268253
- Sponsor
- Stemline Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-10
- Primary completion
- 2023-03-27
- Enrollment
- 82
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.